Last updated: February 27, 2026
What is NDC 49348-0893?
NDC 49348-0893 corresponds to Galsulfase, marketed as Naglazyme. It is an enzyme replacement therapy approved by the FDA for treating Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), a rare genetic disorder characterized by accumulation of glycosaminoglycans leading to tissue damage.
Market Overview
Therapeutic Scope
- Rarity and Patient Population: Maroteaux-Lamy syndrome affects approximately 1 in 1,000,000 worldwide. Estimated US prevalence is fewer than 100 patients.
- Treatment Landscape: Galsulfase is the only FDA-approved therapy for this condition. No generic alternatives are available.
- Market Size: The global rare disease enzyme therapy market for lysosomal storage disorders (LSDs) is projected to reach USD 4.5 billion by 2026, growing at a CAGR of 7%, driven by high unmet needs and expanding approvals.
Competitive Position
- Market Share: Galsulfase holds exclusive rights to its niche. The lack of alternatives sustains high pricing.
- Pricing Benchmarks: Comparable enzyme therapies for LSDs, such as Ertugliflozin and Lumizyme, are priced between USD 300,000 and USD 700,000 annually per patient.
Price Analysis
Current Pricing
- List Price: Approximate wholesale acquisition cost (WAC) of Galsulfase is USD 400,000–USD 500,000 per year per patient.
- Pricing Factors: Cost reflects enzyme production complexity, orphan drug status, limited patient base, and high manufacturing costs.
Reimbursement & Access
- Insurance Coverage: Reimbursement rates are high given the rare disease indication, with payers often covering the full cost for approved patients.
- Patient Access Programs: Manufacturer programs assist with affordability, mitigating financial barriers for eligible patients.
Price Projection and Market Dynamics
Short-term (Next 1-2 Years)
- Stable Pricing: No imminent patent challenges or biosimilar entries forecasted. Current pricing likely to remain within USD 400,000–USD 500,000.
- Influencing Factors: Market exclusivity and PBM negotiations maintain high prices; regulatory changes or new approvals could impact pricing.
Medium-term (3-5 Years)
- Biosimilar Entry: Limited potential for biosimilars due to small patient population, high development costs, and regulatory hurdles.
- Pricing Trends: Slight downward pressure may occur if payers negotiate discounts or if new treatments emerge for related indications.
Long-term (5+ Years)
- Market Expansion: Possible expansion into other indications or broader lysosomal storage disorders could dilute pricing pressure.
- Pricing Outlook: Sustained high prices, around USD 400,000–USD 600,000 annually, supported by the scarcity and high unmet need.
Risks Influencing Price Trends
- Regulatory decisions (e.g., orphan drug extensions or patent challenges).
- Market entry of biosimilars or alternative therapies.
- Changes in reimbursement policies favoring cost containment.
- Advances in gene therapy offering potential curative approaches that could reduce demand.
Key Data Summary
| Aspect |
Details |
| Current annual price per patient |
USD 400,000–USD 500,000 |
| Market size (globally) |
USD 4.5 billion by 2026 |
| Expected CAGR (market) |
7% |
| Patient population (US) |
< 100 |
| Competition |
None currently present |
| Patent status |
Patent protection until 2030 (expected expiration) |
Key Takeaways
- Galsulfase (NDC 49348-0893) remains a high-priced, niche enzyme therapy for a rare disease.
- Its market exclusivity and absence of biosimilars uphold current pricing levels.
- Future pricing stability is probable unless new gene therapies or regulatory shifts occur.
- Market size growth hinges on expanding indications and diagnostic rates, not on price reductions.
FAQs
1. Is there potential for biosimilar competition for Galsulfase?
Limited, due to small patient population, high development costs, and regulatory complexities of biosimilar approval for rare diseases.
2. How does regulatory exclusivity impact pricing?
Patent protections and orphan drug designation extend market monopoly, allowing sustained high prices.
3. What factors could lead to price reductions?
Introduction of gene therapies offering a cure, biosimilars entering the market, or reimbursement policies favoring cost containment.
4. How does the small market size affect pricing?
Limited patient population maintains high per-unit prices due to fixed R&D and manufacturing costs spread over few patients.
5. What is the outlook for the global market?
Expansion into Asia and Europe could increase sales volumes, but prices are likely to remain stable given regulatory and reimbursement structures.
References
- U.S. Food and Drug Administration. (2020). FDA Approvals for Rare Diseases.
- MarketWatch. (2022). Global Lysosomal Storage Disorder Market Analysis.
- EvaluatePharma. (2022). Enzyme Replacement Therapy Market Reports.
- FDA. (2018). Drug development and approval for niche therapies.
- Orphanet. (2020). Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
